Adaptive Biotechnologies Corporation
01/12/2026 | Press release | Distributed by Public on 01/12/2026 07:16
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results (Form 8-K)
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume
SEATTLE, January 12, 2026 - (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.
| • |
Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024. |
| • |
MRD revenue for the fourth quarter and full year 2025 was approximately $62 million and $212 million, representing an increase of 54% and 46%, respectively, over the corresponding periods in 2024. Excluding MRD regulatory milestone revenue, MRD revenue for full year 2025 grew 45% over the corresponding period in 2024. |
| • |
clonoSEQ test volume increased 43% to approximately 30,000 tests in the fourth quarter 2025 compared to the fourth quarter 2024 and ended the year with approximately 105,600 tests delivered, up 39% compared to full year 2024. |
| • |
Cash, cash equivalents and marketable securities were approximately $227 million as of December 31, 2025.1 |
"2025 was a pivotal year for Adaptive, marked by accelerating momentum across our MRD business driven by strong growth in clonoSEQ adoption," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "As we look ahead to 2026, we are well-positioned to extend our leadership in MRD testing, sustain strong clonoSEQ volume and ASP growth, and further expand MRD profitability."
Adaptive Biotechnologies plans to release its complete fourth quarter and full year 2025 financial results during its earnings call in February 2026.
| 1 |
Excludes Digital Biotechnologies, Inc. cash and cash equivalents. |
Adaptive Biotechnologies Corporation published this content on January 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 12, 2026 at 13:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]